Palazestrant
Product Specifications
CAS Number
2092925-89-6
Target
Estrogen/progestogen Receptor, Estrogen Receptor/ERR
Related Pathways
Endocrinology/Hormones
Purity
0.9755
Bioactivity
Palazestrant (OP-1250) is an orally available and highly potent estrogen receptor antagonist and selective ER degrader with antitumor activity.Palazestrant inhibits 17b-estradiol (E2), inhibits MCF7 and CAMA-1 cell proliferation, and can be used in breast cancer research.
Smiles
C(C(C)(C)F)N1[C@@H](C2=C(C=3C(N2)=CC=CC3)C[C@H]1C)C4=CC=C(OC5CN(CCC)C5)C=C4
Molecular Formula
C28H36FN3O
Molecular Weight
449.6
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS9228706-02 5x 0.5 mg
ERBB2 Blocking Peptide (C-term S1050/S1051)
Sign In for Pricing
View Details MBS6188606-01 0.1 mL
MASTL (MASTL, GW, GWL, THC2, Serine/threonine-protein kinase greatwall, Microtubule-associated serine/threonine-protein kinase-like) (MaxLight 405)
Sign In for Pricing
View Details MBS6188606-02 5x 0.1 mL
MASTL (MASTL, GW, GWL, THC2, Serine/threonine-protein kinase greatwall, Microtubule-associated serine/threonine-protein kinase-like) (MaxLight 405)
Sign In for Pricing
View Details 
036546-ML750 100 µL
HIC2, ID (HIC2, HRG22, KIAA1020, ZBTB30, Hypermethylated in cancer 2 protein, HIC1-related gene on chromosome 22 protein, Hic-3, Zinc finger and BTB domain-containing protein 30) (MaxLight 750) discontinued
Sign In for Pricing
View Details